perpetuity. All rights reserved. No reuse allowed without permission.

# SARS-CoV-2 infection drives a glycan switch of peripheral T cells at diagnosis.

3 Inês Alves<sup>1,2,3\$</sup>, Manuel M. Vicente<sup>1,2,4\$</sup>; Joana Gaifem<sup>1,2</sup>, Ângela Fernandes<sup>1,2</sup>, Ana M. Dias<sup>1,2</sup>,

4 Cláudia S. Rodrigues<sup>1,2</sup>, José Carlos Oliveira<sup>5</sup>, Nair Seixas<sup>6</sup>, Luis Malheiro<sup>7</sup>, Miguel A. Abreu<sup>4,8</sup>;

5 Rui Sarmento e Castro<sup>4,8</sup>; Salomé S. Pinho<sup>1,2,3,4,9\*</sup>

6 <sup>1</sup> Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal

7 <sup>2</sup> i3S – Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal.

**8** <sup>3</sup> Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.

<sup>4</sup> Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.

<sup>5</sup> Department of Clinical Pathology, Centro Hospitalar Universitário do Porto, 4099-001 Porto, Portugal.

<sup>6</sup> Department of Clinical Pathology, Centro Hospitalar Vila Nova de Gaia/Espinho, 4434-502 Gaia, Portugal

12 <sup>7</sup> Department of Infectious Diseases, Centro Hospitalar Vila Nova de Gaia/Espinho, 4434-502 Gaia, Portugal

13<sup>8</sup> Department of Infectious Diseases, Centro Hospitalar Universitário do Porto, 4099-001 Porto, Portugal.

- <sup>9</sup>Lead Contact
- 15 \$These authors contributed equally

\*Corresponding author: <u>salomep@ipatimup.pt</u> (S.S.P)
17

Grant Support: The Institute of Molecular Pathology and Immunology of the 18 University of Porto integrates the Institute for Research and Innovation in Health (i3S) 19 research unit, which is partially supported by the Portuguese Foundation for Science 20 and Technology (FCT). This article was partially funded by the FCT, in collaboration 21 22 with the Portuguese Agency for Clinical Research and Biomedical Innovation (AICIB) under the special funding, "RESEARCH 4 COVID-19" Project #006 granted to the PI 23 Salomé S. Pinho. IA [SFRH/BD/128874/2017] and MV [PD/BD/135452/2017] 24 received funding from the FCT. 25

26 **Running Title:** T cell glycan switch in SARS-CoV-2 infection

# 27 Abstract

COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in 28 different clinical manifestations ranging from asymptomatic/mild to severe disease that 29 requires hospitalization. Here, we demonstrated that SARS-CoV-2 infection results in a 30 glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a 31 specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently 32 triggered by a serological factor. This specific glycan switch of T cells is detected at 33 diagnosis being more pronounced in asymptomatic patients. We further demonstrated 34 that asymptomatic patients display an increased expression of a viral-sensing receptor, 35 through the up-regulation of DC-SIGN in monocytes. We showed that higher levels of 36 DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. These 37 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. new evidences pave the way to the identification of a novel glycan-based response in T 38

cells that may confer protection against SARS-CoV-2 infection in asymptomatic 39

40 patients, highlighting a novel prognostic biomarker and potential therapeutic target.

Keywords: asymptomatic / DC-SIGN / glycan-recognition receptors / N-glycosylation / 41

42 prognosis / SARS-CoV-2 / T-cell activation

43

#### Introduction 44

Coronavirus SARS-CoV-2 is the etiologic agent responsible for the global pandemic of 45 Coronavirus disease 2019 (COVID-19), that, as of 9<sup>th</sup> of February, has infected over 46 106 million people worldwide(1, 2). The overall mortality of COVID-19 is between 47 0.5% and 3.5%(1, 2). COVID-19 is a highly selective disease. In fact, only some 48 infected individuals get sick, and although most of the critically ill are elderly, some 49 patients that die are previously healthy and/or relatively young(3). There is an urgent 50 need to improve the understanding of the pathophysiology of this disease, envisioning 51 52 better management in terms of patients care, treatment options, vaccination strategies and the allocation of healthcare resources. Vaccine development against SARS-CoV-2 53 poses a great promise for the resolution of the pandemic, and several vaccines are now 54 being distributed among the world population, namely mRNA- and protein-based 55 approaches(4, 5). However, its long-term protection, effectiveness to re-infection, 56 efficacy to new variants and availability for the general public is still on trial. This lack 57 of knowledge highlights the importance of understanding patient-specific immune 58 response to infection, envisioning the identification of novel mechanisms of disease. 59 Moreover, comprehensive insights on COVID-19 molecular mechanism may be 60 61 translated into diagnostic or prognostic biomarkers, therapeutic targets to improve 62 patient's clinical management and patients' stratification for vaccination.

SARS-CoV-2 infection results in a broad range of symptoms(6). Several studies on 63 immune profiling of infected patients consistently revealed an immunological 64 dysregulation, observed in peripheral blood mononuclear cells (PBMCs). A decrease of 65 T cells and dendritic cells frequencies and an increase of monocytes and neutrophils 66 have been observed in hospitalized infected individuals, as well as a cytokine 67 dysregulation, the so-called "cytokine storm" associated with critical illness(7-10). 68

However the mechanism underlying this immunological dysregulation remains largelyunknown.

Despite overlooked, the field of glycobiology can provide missing answers to 71 72 immunological questions. Glycosylation is a major post-translational mechanism characterized by the enzymatic addition of glycans (carbohydrates) to proteins or lipids 73 74 of essentially all cells, including immune cells. In fact, glycans are master regulators of immune cell functions, defining the activation and differentiation of T cells(11, 12). In 75 the cellular immune system, we and others have previously demonstrated the regulatory 76 power of glycans in adaptive immune response through the modulation of T cell 77 activation thresholds associated with the immunopathogenesis of autoimmune diseases 78 79 and cancer (13-19). Moreover, being present in several pathogens, glycans can also be sensed by immune cells, through their recognition by specific glycan-recognizing 80 81 receptors expressed in those cells(20). Like the majority of viruses, SARS-CoV-2 viral capsids are also covered with glycans. More specifically, the spike protein of the SARS-82 CoV-2 envelope was shown to be highly glycosylated (harboring 22 N-glycosylation 83 84 sites) with glycan structures such as oligomannose and some branched N-glycans(21, 22). These structures can be specifically recognized by glycan binding proteins (GBPs) 85 of host's immune cells, such as the C-type-lectin Dendritic Cell-Specific Intercellular 86 87 adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), present in innate immune cells, promoting virus recognition and elimination(23, 24). 88

Defining the glycosylation profiles of immune cells in SARS-CoV-2 infected individuals and how they impact their effector functions remains completely unknown, being of utmost importance for the understanding of COVID-19 immunopathogenesis, as well as for the improvement of the clinical management of the disease and for pandemic control measures, namely as a stratification biomarker.

In this study, we discovered that circulating T cells exhibit a glycan switch upon SARS-CoV-2 infection that is detected at COVID-19 diagnosis. This change in the glycosylation profile of T cells appears to be triggered by a serum inflammatory factor present in infected patients. This specific T cell glycan switch is more pronounced in asymptomatic patients, rather than in those who exhibit symptoms. Importantly from a clinical standpoint, we also unveiled that COVID-19 patients with good prognosis exhibit an upregulation of DC-SIGN expression in circulating monocytes.

101

# 102 Material and Methods

103 Cohort description and patient's selection criteria

The present study integrates a total of 32 patients diagnosed with SARS-CoV-2 from 2 individual Portuguese cohorts (between May 2020 and July 2020), 20 patients from Infectious Disease Department, Centro Hospitalar e Universitário do Porto (CHUP), Porto, Portugal and 12 patients from Infectious Disease Department, Centro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG), Vila Nova de Gaia, Portugal. The total cohort includes patients of both genders and age between 22 and 89 years old. All the samples were included in all the FACS analysis discussed.

Blood was collected and plasma and PBMCs were isolated at the time of diagnosis and 14 days (n=6) after diagnosis. Similar analysis was conducted in a subset of patients (n=2) that recovered.

The eligibility criteria for inclusion in this study were SARS-CoV-2 positive 114 patients asymptomatic or symptomatic with different levels of severity (mild, moderate 115 116 and severe). Asymptomatic patients (n=5) were defined as positive for the SARS-CoV-2 PCR test, but no signs of diseases. The following criteria were used to stratify 117 118 symptomatic SARS-CoV-2 patients in terms of the disease severity and accordingly with WHO guidelines (25); 1- MILD (n=18): individuals with no evidences of 119 120 pneumonia; 2- MODERATE (n=6): individuals without need of invasive mechanical 121 ventilation and without need of admission to hospital intensive care unit, but evidence of pneumonia and need of supplemental oxygen; 3- SEVERE (n=1): individuals with 122 123 need of invasive mechanical ventilation and with need of admission to hospital intensive care unit. Patients demographic and relevant clinical data are summarized in 124 125 table 1.

Healthy controls (n=5) are represented by volunteer individuals with no historyof infection disorders that underwent CHUP for routine analysis.

All participants gave informed consent about all clinical procedures and researchprotocols were approved by the ethics committee of CHUP and CHVNG, Portugal.

130

131 Human PBMCs isolation

Human peripheral blood mononuclear cells (PBMCs) from COVID-19 patients and 132 healthy donors were isolated by gradient centrifugation using 1 volume of 133 Lymphoprep<sup>TM</sup> (Stemcell Technologies) for 2 volumes of blood, 30 minutes at 900 x g 134 with the brake off. The upper phase, containing the serum, was collected and stored at -135 80°C. PBMCs (interphase) were collected, washed twice with PBS and incubated with 136 137 FVD-APC-eFluor780 (eBioscience) for 30 minutes. Cells were washed with PBS, fixed with 2% formaldehyde (PanReac ApplieChem) and resuspended in FACS buffer (PBS 138 139 2%FBS). All procedures were performed under biosafety level 3 (BSL3) conditions.

#### **Flow Cytometry Staining** 140

For lectin staining, cells were incubated with conjugated lectins (Vector 141 Laboratories): Phaseolus Vulgaris leucoagglutinin (L-PHA-fluorescein, FITC), 142 143 Galanthus Nivalis lectin (GNA-fluorescein, FITC), biotinylated Sambucus Nigra lectin (SNA) and biotinylated Aleuria aurantia lectin (AAL) for 15 minutes. Biotinylated 144 lectins were incubated with streptavidin-PE-Cy7 (eBioscience) for 30 minutes. For 145 surface marker staining, cells were stained for 30 minutes on ice while protected from 146 light with the following antibodies: APC anti-human TCRyδ (clone B1), BV510 anti-147 human CD69 (clone FN50), PE anti-human CD25 (clone BC96), BV421 anti-human 148 CD14 (clone 63D3), PE anti-human CD56 (clone HCD56), PE-Cy7 anti-human CD206 149 (clone 15-2) from Biolegend; eFluor<sup>TM</sup> 450 anti-human CD4 (clone RPA-T4), PerCP-150 eFluor<sup>TM</sup> 710 anti-human PD-1 (clone J105), PE-Cy5 anti-human CD19 (clone HIB19), 151 eFluor<sup>TM</sup> 450 anti-human IgM (clone SA-DA4), eFluor<sup>TM</sup> 660 anti-human galectin 3 152 153 (clone M3/38), APC anti-human CD11c (clone BU15), PE-Cy5 anti-human CD86 (clone IT2.2) from eBioscience; PE anti-human TCR $\alpha/\beta$  (clone BW242/412) from 154 Miltenvi; BV510 anti-human CD3 (clone OKT3) from BD Biosciences; for DC-SIGN 155 staining, cells were incubated with DC-SIGN rabbit IgG (Biorad) followed by 156 157 incubation with polyclonal swine anti-rabbit IgG (FITC; Dako) for 30 minutes on ice. Cells were resuspended in FACS buffer prior analysis. Data were obtained on a BD 158 FACS Canto II instrument (Becton Dickinson) and analyzed using FlowJo v10.0 (Tree 159 160 Star Inc.).

### In vitro assessment of glycan modulation of T cells 161

PBMCs from healthy and independent from the COVID-19 cohirt human donors 162 163 were isolated from fresh collected blood, as described above. PBMCs were cultured in

RPMI-1640 (Gibco) supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 164 165 1% penicillin/streptomycin and 10% of plasma from 4 asymptomatic or moderate patients, for each condition. Different cell culture conditions were tested, namely human 166 plasma concentration (25% and 10%) as well as time of culture (4 days, 2 days, 24h and 167 12h). The optimal culture condition (with lower cell death and stronger glycan 168 modulation) was selected (10% human plasma and 24h cell culture). After 24h cell 169 glycoprofile was evaluated using the same antibodies and lectin panel selected above. 170 171 Data were obtained on a BD FACS Canto II instrument (Becton Dickinson) and 172 analyzed using the FlowJo 10.0 software (Tree Star Inc.).

173

# 174 Data visualization and statistical analysis

Data visualization and statistical analyses (non-parametric Mann-Whitney t-test)
were done using GraphPad Prism 9 software.

The prediction capacity of DC-SIGN levels to discriminate patients who develop a 177 poor disease course from those that have a good disease course was determined by 178 179 plotting the receiver operating characteristic (ROC) curves and calculating the area under the curve (AUC). The cut-off that revealed the best balance between sensitivity 180 and specificity was selected for the subsequent statistical analysis. Sensitivity, 181 specificity, and positive and negative predictive values were calculated. Univariate 182 183 binary logistic regression analysis was performed to test DC-SIGN levels and disease 184 progression (good: asymptomatic maintained asymptomatic and/or severity decreased at least one category; poor: symptoms were not improved and/or escalate to a higher 185 186 severity). In logistic regression, model goodness-of-fit was assessed by the Hosmer-Lemeshow statistic and test. Results are presented as odds ratios (ORs) for each 187 188 category as compared with a predefined reference category, and their respective 95% confidence intervals (CIs). Odds ratios above one and below one are indicative, 189 190 respectively, of higher and lower odds of develop poor disease course as compared with a reference category. Statistical analysis was performed using the statistical software 191 192 SPSS version 25 (IBM Corp., IBM SPSS Statistics for Windows, Version 25.0, Armonk, NY; released 2017) The threshold used for statistical significance was p-193 value< 0.05. 194

#### **Results** 195

### SARS-CoV-2 infected individuals display decreased **B1,6-GlcNAc** branched and 196 a2,6-sialic acid N-glycans on peripheral T cells at diagnosis. 197

Taking into consideration the fact that it is still unclear the underlying mechanisms that 198 explain a differential inter-individual clinical presentation of COVID-19 at diagnosis, 199 we herein characterized the glycosylation profile of T cells from patients' peripheral 200 201 blood. A lectin-based flow cytometry of the T cell populations was performed to evaluate glycosylation profiles. We started by analysing the levels of expression of 202 203 ß1,6-GlcNAc branched N-glycan structures, known to have a major impact on the regulation of T cell activity and function(13, 16, 26), using the L-PHA lectin. Our 204 205 results demonstrated that, overall, T cells from infected (IF) subjects have a decrease in 206 branched N-glycan structures, particularly on CD8<sup>+</sup> and  $\gamma\delta$  T cells, when compared to 207 non-infected (non-IF) ones (Figure 1A, top and bottom left panel). Moreover, T cells 208 from asymptomatic patients have lower levels of B1,6-GlcNAc branched N-glycans, that gradually tend to increase along disease severity (Figure 1A, right). Notably, CD8<sup>+</sup> T 209 210 cells display a significant decrease in the levels of expression of complex branched Nglycans in asymptomatic and mild disease patients, when compared to non-IF 211 212 individuals (Figure 1A, top).

Concerning  $\alpha 2,6$ -sialylation (recognized by the SNA lectin), already described to play a 213 214 role in the regulation of T cells immune response(27), our results demonstrate that 215 CD8<sup>+</sup> T cells from IF patients display a significant decreased SNA binding, in 216 comparison with non-IF individuals (Figure 1B, top left). Consistently, asymptomatic patients present the lowest levels of SNA binding compared to non-IF (Fig.1B, top 217 right). Even though the levels of SNA binding were shown to be associated with age 218 (Supplemental Figure 1E), there are no significant differences between the mean age 219 220 of asymptomatic and symptomatic patients (Supplemental Table 1). Curiously, for both glycans, the two COVID-19 convalescent patients seem to recover (or surpass) the 221 222 levels of expression of  $\beta$ 1.6-GlcNAc branched and  $\alpha$ 2.6-sialic acid glycan structures in all T cell subsets (Fig. 1A and B, right). These results showed that CD8<sup>+</sup>T cells from 223 224 asymptomatic patients display a defect in branched and sialylated N-glycans when 225 compared with non-IF.

The differences observed in the glycosylation profile of T cells across severity, were not related to the abundance or activation of T cell populations, since CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup> and  $\gamma\delta$  T cells showed similar frequencies as well as similar levels of PD1 and CD69 expression between the groups, with the exception of lowered CD3<sup>+</sup> population and increased CD69<sup>+</sup> within CD8<sup>+</sup> T cells, in the mild disease group (**Supplemental Figure 1A, B and C**).

In addition, and since glycosylation is a dynamic process that can change along with disease status, we took advantage of a limited longitudinal follow-up analysis using a single patient, representative of each severity group (asymptomatic, mild, moderate and severe), which revealed that levels of expression of  $\beta$ 1,6-GlcNAc and  $\alpha$ 2,6-sialylation are restored in patients that improved disease severity at day 14 post-diagnosis (**Supplemental Figure 1D**).

No major differences were observed for other glycan structures such as fucosylation
(AAL binding) or mannosylation (GNA binding) in the different T cell subsets at
diagnosis (Supplemental Figure 1A and B).

241 These results showed that SARS-CoV-2 infected individuals led to an en bloc decreased expression of specific glycan structures such as B1,6-GlcNAc branched N-glycans and 242 α2,6-sialic acid in T cells, predominately in CD8<sup>+</sup> T cells and asymptomatic patients. 243 The absence of differences on high mannose structures (GNA binding) or fucose 244 245 residues on T cells (AAL binding), support the specificity of the glycan switch. In fact, 246 decreased levels of  $\beta$ 1,6-branched N-glycans in T cells have been pointed out as a 247 mechanism of TCR threshold regulation, by hampering the TCR complex clustering and lowering the necessary amount of antigen-recognition to signal a cellular response(28). 248 Moreover, surface  $\alpha 2,6$ -sialylation also regulates T cell immune response through 249 250 galectins binding modulation(29–31).

In order to further clarify the underlying mechanism that imposes the changes in the glycosylation profile of circulating T cells upon SARS-CoV-2 infection, we have performed an *in vitro* assay, in which PBMCs isolated from healthy individuals were co-cultured with plasma from 4 patients from either each group: non-IF, asymptomatic or moderate disease. Our results showed that T cells, upon co-culture with plasma from asymptomatic patients displayed a significant decreased expression of  $\beta$ 1,6-GlcNAc branched *N*-glycans (**Figure 2A**) and  $\alpha$ 2,6-sialylation (**Figure 2B**), when compared to T

cells cultured with plasma from non-IF individuals and moderate disease patients. These 258 259 results suggest the existence a specific serum factor that in asymptomatic patients drives 260 a remarkable drop of complex branched and sialylated glycans structures on T cells. In 261 fact, it is known that asymptomatic patients display a differential serum composition of cytokines and chemokines, when compared to symptomatic (32, 33). Moreover, T cell 262 glycosylation is known to be modulated by specific interleukins, namely IL-2 and IL-7 263 that regulate the transcription of specific Golgi glycosyltransferases(17, 25), which 264 265 renders the hypothesis that an extracellular factor could be mediating the T cells glycan 266 switch in a more efficient manner in asymptomatic than symptomatic patients.

267

# 268 Levels of DC-SIGN expression in circulating monocytes predict COVID-19 prognosis

269 To gain further insights in the viral-glycan recognition mechanism, we have characterized the expression of specific GBPs expressed by innate immune cells that are 270 known to sense and recognize specific viral glycans, instructing an immune 271 response(34). Regarding the abundance of innate cells, we have observed an increase in 272 273 the frequency of dendritic cells (DCs) as well as monocytes (Mo) in asymptomatic 274 patients, when compared to Non-IF individuals, and no differences in terms of NK and 275 NK-T cells subsets (Supplemental Figure 1B). Regarding their activation state, 276 analysed by CD86 expression, only monocytes are shown to be activated in asymptomatic and mild disease patients (Supplemental Figure 1C). This is in 277 278 accordance with previous findings(35).

Specifically, DC-SIGN, a C-type-lectin that recognizes mannose structures, is already known to play a role in the SARS-COV-2 recognition(24), being expressed by monocytes, immature DCs and macrophages. Our results showed that patients from the asymptomatic group displayed higher levels of DC-SIGN expression in monocytes compared moderate disease (**Figure 3A**), suggesting an increased capacity of asymptomatic patients to sense and recognize the virus.

Taking into consideration the biological relevance of DC-SIGN expression in monocytes as the first sensing mechanism upon SARS-CoV-2 infection, and given the heterogenous expression of DC-SIGN among infected individuals (at diagnosis), (Figure 3A) we next analysed its prognostic value. A longitudinal cohort was used with

clinical information in terms of disease progression (development of a poor versus good 289 290 prognosis at day 14 post-diagnosis, characterized in Supplementary Table 1). 291 Remarkably, the expression levels of DC-SIGN in monocytes were found to be able to 292 stratify patients at diagnosis in terms of their likelihood of developing a good versus a poor disease prognosis with a specificity and sensitivity of 78.9% and 63.6%, 293 294 respectively (Figure 3B). The univariate analysis demonstrated that high levels of DC-295 SIGN expression in monocytes at diagnosis increase the odds ratio (OD) associated 296 with the prediction of having a good prognosis, OD = 6.548 p-value = 0.011. In fact, the 297 recognition of the coronaviruses' glycans by innate immune cells was demonstrated to 298 be mediated by DC-SIGN(23, 24). An increased expression of this C-type-lectin at the 299 initial days of infection suggests a more efficient viral recognition and subsequent 300 clearance, resulting in a good prognosis of the disease.

301

#### Discussion 302

303 Our results demonstrated for the first time that SARS-CoV-2 infection imposes a 304 glycosylation reprogramming of adaptive immune cells suggesting a specific glycan 305 switch of T cells that may define their ability to successfully deal with infection. We 306 identified a specific glycosylation signature of circulating T cells that is associated with 307 their activity and function, distinguishing infected patients from non-infected individuals. Our results also suggest that the glycan switch imprinted in circulating T 308 309 cells could be mediated by a serum extracellular factor(s), occurring just after SARS-310 CoV-2 infection (Supplemental Figure 2). In fact, previous evidences from others and us demonstrated that the deficiency in branched N-glycan structures on T cells imposes 311 312 a hyper-reactive phenotype with decreased threshold of T cell activation and increased T cell activity(13, 28). We herein propose that the immune response against SARS-313 CoV-2 infection appears to be influenced by the glycosylation profile of circulating T 314 315 cells which defines their effective functions. In fact, a pronounced deficiency of complex branched and sialylated glycans on CD8<sup>+</sup> and  $\gamma\delta$  T cells were observed in 316 asymptomatic COVID-19 patients. This dynamic and plastic glycoimmune modulation 317 ("Glyco-Immune Alert" mechanism) may constitute a novel mechanism of host-318 response, that contributes to further understand the immunological differences among 319 320 infected individuals(36).

Furthermore, we also showed another glycan-based mechanism of host response to SARS-CoV-2 driven by the upregulation of the viral's glycans recognizing receptor DC-SIGN in monocytes, with prognostic application when detected at diagnosis.

This study unlocks the identification of a specific glycosignature of T cells as well as a 324 prognostic biomarker in COVID-19. Further studies are needed to explore the 325 326 mechanistic impact of the T cell glycan switch in infection and along disease course. Moreover, it is fundamental to identify the critical serological factor(s) that instructs this 327 T cells glyco-reprogramming, as a potential new biomarker and therapeutic target. Our 328 study was conducted during the first wave of COVID-19 (March-July 2020) having a 329 limitation in terms of sample size, indicating the need to validate these promising 330 331 observations in larger and well-characterized multicentric cohorts as well as analysing the impact of other SARS-CoV-2 variants in T cells glycan switch. 332

These new evidences in COVID-19 pave the way to the identification of a specific blood glycosignature able to stratify patients at diagnosis according with their risk to evolve to worsen disease. This will certainly contribute to improve vaccination strategy and patients risk stratification, optimizing an effective allocation and management of health care resources such as ventilators and intensive care facilities.

Acknowledgments: We would like also to thank to all the Portuguese clinicians involved in COVID-19 patients 'care, with a special thanks to those from CHUP and CHVNG that directly or indirectly contributed to this work (Dr. Tiago Teixeira from CHVNG) and to all the patients that accepted to participate in this study. We also acknowledge the nurses and technicians that collaborated in the collection of the samples, especially Nurse Teresa Cruz from CHUP.

Author contributions: IA, MV and SSP designed research. IA, MV, JG, AF, AMD and
CSR performed research. SSP contributed new reagents/analytical tools. NS, LM, MAA
and RSC provided and characterized clinical samples. IA and MV analysed data. IA,
MV and SSP wrote the manuscript with contributions from all authors.

- 348 **Conflict of interests:** The authors declare no competing financial interests.
- 349

350 **References** 

- 1. WHO. Dashboard | WHO Coronavirus Disease (COVID-19).
- 352 2. Dong, E., H. Du, and L. Gardner. 2020. An interactive web-based dashboard to track
- 353 COVID-19 in real time. *Lancet. Infect. Dis.* 20: 533–534.
- 354 3. Wu, Z., and J. M. McGoogan. 2020. Characteristics of and Important Lessons From
- the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
- 356 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 323:
- 357 1239–1242.
- 4. Baden, L. R., H. M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert,
- 359 S. A. Spector, N. Rouphael, C. B. Creech, J. McGettigan, S. Kehtan, N. Segall, J. Solis,
- 360 A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D.
- 361 Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B. S. Graham, H.
- 362 Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, H. Zhou, S. Han, M. Ivarsson, J.
- 363 Miller, T. Zaks, and COVE Study Group. 2020. Efficacy and Safety of the mRNA-1273
- 364 SARS-CoV-2 Vaccine. N. Engl. J. Med.
- 5. Polack, F. P., S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L.
  Perez, G. Pérez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S.
  Roychoudhury, K. Koury, P. Li, W. V Kalina, D. Cooper, R. W. Frenck, L. L. Hammitt,
  Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U.
  Şahin, K. U. Jansen, W. C. Gruber, and C4591001 Clinical Trial Group. 2020. Safety
  and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J. Med.* 383: 2603–2615.
- 6. Guan, W., Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, D. S. C.
  Hui, B. Du, L. Li, G. Zeng, K.-Y. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. Xiang,
  S. Li, J. Wang, Z. Liang, Y. Peng, L. Wei, Y. Liu, Y. Hu, P. Peng, J. Wang, J. Liu, Z.
  Chen, G. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu, and N. Zhong. 2020. Clinical
  Characteristics of Coronavirus Disease 2019 in China. *N. Engl. J. Med.* 382: 1708–
  1720.
- 378 7. Laing, A. G., A. Lorenc, I. del Molino del Barrio, A. Das, M. Fish, L. Monin, M.
- 379 Muñoz-Ruiz, D. R. McKenzie, T. S. Hayday, I. Francos-Quijorna, S. Kamdar, M.
- Joseph, D. Davies, R. Davis, A. Jennings, I. Zlatareva, P. Vantourout, Y. Wu, V. Sofra,
- 381 F. Cano, M. Greco, E. Theodoridis, J. Freedman, S. Gee, J. N. E. Chan, S. Ryan, E.

- Bugallo-Blanco, P. Peterson, K. Kisand, L. Haljasmägi, L. Chadli, P. Moingeon, L.
- 383 Martinez, B. Merrick, K. Bisnauthsing, K. Brooks, M. A. A. Ibrahim, J. Mason, F.
- 384 Lopez Gomez, K. Babalola, S. Abdul-Jawad, J. Cason, C. Mant, J. Seow, C. Graham,
- 385 K. J. Doores, F. Di Rosa, J. Edgeworth, M. Shankar-Hari, and A. C. Hayday. 2020. A
- dynamic COVID-19 immune signature includes associations with poor prognosis. *Nat.*
- 387 *Med.* 1–13.
- 388 8. Zhou, R., K. K.-W. To, Y.-C. Wong, L. Liu, B. Zhou, X. Li, H. Huang, Y. Mo, T.-Y.
- Luk, T. T.-K. Lau, P. Yeung, W.-M. Chan, A. K.-L. Wu, K.-C. Lung, O. T.-Y. Tsang,
- 390 W.-S. Leung, I. F.-N. Hung, K.-Y. Yuen, and Z. Chen. 2020. Acute SARS-CoV-2
- Infection Impairs Dendritic Cell and T Cell Responses. *Immunity* 53: 864–877.
- 392 9. Lucas, C., P. Wong, J. Klein, T. B. R. Castro, J. Silva, M. Sundaram, M. K.
- 393 Ellingson, T. Mao, J. E. Oh, B. Israelow, T. Takahashi, M. Tokuyama, P. Lu, A.
- 394 Venkataraman, A. Park, S. Mohanty, H. Wang, A. L. Wyllie, C. B. F. Vogels, R.
- 395 Earnest, S. Lapidus, I. M. Ott, A. J. Moore, M. C. Muenker, J. B. Fournier, M.
- 396 Campbell, C. D. Odio, A. Casanovas-Massana, R. Herbst, A. C. Shaw, R. Medzhitov,
- 397 W. L. Schulz, N. D. Grubaugh, C. Dela Cruz, S. Farhadian, A. I. Ko, S. B. Omer, and
- A. Iwasaki. 2020. Longitudinal analyses reveal immunological misfiring in severe
  COVID-19. *Nature* 584: 463–469.
- 400 10. Mehta, P., D. F. McAuley, M. Brown, E. Sanchez, R. S. Tattersall, J. J. Manson, and
- 401 U. HLH Across Speciality Collaboration. 2020. COVID-19: consider cytokine storm
- 402 syndromes and immunosuppression. *Lancet (London, England)* 395: 1033–1034.
- 403 11. Pereira, M. S., I. Alves, M. Vicente, A. Campar, M. C. Silva, N. A. Padrão, V.
- 404 Pinto, Â. Fernandes, A. M. Dias, and S. S. Pinho. 2018. Glycans as Key Checkpoints of
- 405 T Cell Activity and Function. *Front. Immunol.* 9: 2754.
- 406 12. Varki, A., R. D. Cummings, J. D. Esko, P. Stanley, G. W. Hart, M. Aebi, A. G.
- 407 Darvill, T. Kinoshita, N. H. Packer, J. H. Prestegard, R. L. Schnaar, and P. H.
- 408 Seeberger. 2015. *Essentials of Glycobiology*, Cold Spring Harbor Laboratory Press.
- 409 13. Dias, A. M., A. Correia, M. S. Pereira, C. R. Almeida, I. Alves, V. Pinto, T. A.
- 410 Catarino, N. Mendes, M. Leander, M. T. Oliva-Teles, L. Maia, C. Delerue-Matos, N.
- 411 Taniguchi, M. Lima, I. Pedroto, R. Marcos-Pinto, P. Lago, C. A. Reis, M. Vilanova, and
- 412 S. S. Pinho. 2018. Metabolic control of T cell immune response through glycans in

413 inflammatory bowel disease. *Proc. Natl. Acad. Sci. U. S. A.* 115: E4651–E4660.

414 14. Silva, M. C., Â. Fernandes, M. Oliveira, C. Resende, A. Correia, J. C. De-Freitas-

415 Junior, A. Lavelle, J. Andrade-da-Costa, M. Leander, H. Xavier-Ferreira, J. Bessa, C.


- 416 Pereira, R. M. Henrique, F. Carneiro, M. Dinis-Ribeiro, R. Marcos-Pinto, M. Lima, B.
- 417 Lepenies, H. Sokol, J. C. Machado, M. Vilanova, and S. S. Pinho. 2020. Glycans as
- 418 Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition
- 419 Preventing Cancer Progression. *Cancer Immunol. Res.* 8: 1407–1425.
- 420 15. Ryan, S. O., and B. A. Cobb. 2012. Roles for major histocompatibility complex
- 421 glycosylation in immune function. *Semin. Immunopathol.* 34: 425–41.
- 422 16. Demetriou, M., M. Granovsky, S. Quaggin, and J. W. Dennis. 2001. Negative
  423 regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. *Nature*424 409: 733–9.
- 17. Mkhikian, H., A. Grigorian, C. F. Li, H.-L. Chen, B. Newton, R. W. Zhou, C.
  Beeton, S. Torossian, G. G. Tatarian, S.-U. Lee, K. Lau, E. Walker, K. A. Siminovitch,
  K. G. Chandy, Z. Yu, J. W. Dennis, and M. Demetriou. 2011. Genetics and the
  environment converge to dysregulate N-glycosylation in multiple sclerosis. *Nat. Commun.* 2: 1–13.
- 430 18. Grigorian, A., S. Torossian, and M. Demetriou. 2009. T-cell growth, cell surface
  431 organization, and the galectin-glycoprotein lattice. *Immunol. Rev.* 230: 232–46.
- 432 19. Pereira, M. S., C. Durães, T. A. Catarino, J. L. Costa, I. Cleynen, M. Novokmet, J.
  433 Krištić, J. Štambuk, N. Conceição-Neto, J. C. Machado, R. Marcos-Pinto, F. Magro, S.
  434 Vermeire, G. Lauc, P. Lago, and S. S. Pinho. 2020. Genetic Variants of the MGAT5
  435 Gene Are Functionally Implicated in the Modulation of T Cells Glycosylation and
  436 Plasma IgG Glycome Composition in Ulcerative Colitis. *Clin. Transl. Gastroenterol.*437 11: e00166.
- 438 20. Van Breedam, W., S. Pöhlmann, H. W. Favoreel, R. J. de Groot, and H. J.
- Nauwynck. 2014. Bitter-sweet symphony: glycan–lectin interactions in virus biology. *FEMS Microbiol. Rev.* 38: 598–632.
- 441 21. Watanabe, Y., Z. T. Berndsen, J. Raghwani, G. E. Seabright, J. D. Allen, O. G.
- 442 Pybus, J. S. McLellan, I. A. Wilson, T. A. Bowden, A. B. Ward, and M. Crispin. 2020.


443 Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. *Nat.*444 *Commun.* 11: 1–10.

- 22. Watanabe, Y., J. D. Allen, D. Wrapp, J. S. McLellan, and M. Crispin. 2020. Sitespecific glycan analysis of the SARS-CoV-2 spike. *Science* 369: 330–333.
- 447 23. Marzi, A., T. Gramberg, G. Simmons, P. Möller, A. J. Rennekamp, M. Krumbiegel,
- 448 M. Geier, J. Eisemann, N. Turza, B. Saunier, A. Steinkasserer, S. Becker, P. Bates, H.
- 449 Hofmann, and S. Pöhlmann. 2004. DC-SIGN and DC-SIGNR interact with the
- 450 glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome
- 451 coronavirus. J. Virol. 78: 12090–5.
- 452 24. Amraie, R., M. A. Napoleon, W. Yin, J. Berrigan, E. Suder, G. Zhao, J. Olejnik, S.
- 453 Gummuluru, E. Muhlberger, V. Chitalia, and N. Rahimi. 2020. CD209L/L-SIGN and
- 454 CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in
- 455 lung and kidney epithelial and endothelial cells. *bioRxiv* 2020.06.22.165803.
- 456 25. Grigorian, A., H. Mkhikian, and M. Demetriou. 2012. Interleukin-2, Interleukin-7, T
  457 cell-mediated autoimmunity, and N-glycosylation. *Ann. N. Y. Acad. Sci.* 1253: 49–57.
- 458 26. Dias, A. M., J. Dourado, P. Lago, J. Cabral, R. Marcos-Pinto, P. Salgueiro, C. R.
- 459 Almeida, S. Carvalho, S. Fonseca, M. Lima, M. Vilanova, M. Dinis-Ribeiro, C. A. Reis,
- and S. S. Pinho. 2014. Dysregulation of T cell receptor N-glycosylation: a molecular
- 461 mechanism involved in ulcerative colitis. *Hum. Mol. Genet.* 23: 2416–27.
- 462 27. Bagriaçik, E. U., and K. S. Miller. 1999. Cell surface sialic acid and the regulation
  463 of immune cell interactions: the neuraminidase effect reconsidered. *Glycobiology* 9:
  464 267–75.
- 28. Demetriou, M., M. Granovsky, S. Quaggin, and J. W. Dennis. 2001. Negative
  regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. *Nature*409: 733–739.
- 29. Pappu, B. P., and P. A. Shrikant. 2004. Alteration of cell surface sialylation
  regulates antigen-induced naive CD8+ T cell responses. *J. Immunol.* 173: 275–84.
- 470 30. Thevarajan, I., T. H. O. Nguyen, M. Koutsakos, J. Druce, L. Caly, C. E. van de
- 471 Sandt, X. Jia, S. Nicholson, M. Catton, B. Cowie, S. Y. C. Tong, S. R. Lewin, and K.

- 472 Kedzierska. 2020. Breadth of concomitant immune responses prior to patient recovery:
- a case report of non-severe COVID-19. *Nat. Med.* 26: 453–455.
- 474 31. Matzinger, P. 2002. The danger model: a renewed sense of self. *Science* 296: 301–5.
- 475 32. Long, Q.-X., X.-J. Tang, Q.-L. Shi, Q. Li, H.-J. Deng, J. Yuan, J.-L. Hu, W. Xu, Y.
- 476 Zhang, F.-J. Lv, K. Su, F. Zhang, J. Gong, B. Wu, X.-M. Liu, J.-J. Li, J.-F. Qiu, J. Chen,
- 477 and A.-L. Huang. 2020. Clinical and immunological assessment of asymptomatic
- 478 SARS-CoV-2 infections. *Nat. Med.* 26: 1200–1204.
- 479 33. Pérez-Cabezas, B., R. Ribeiro, I. Costa, S. Esteves, A. R. Teixeira, T. Reis, R.
- Monteiro, A. Afonso, V. Pinheiro, M. I. Antunes, M. L. Araújo, J. N. Ribeiro, A.
  Cordeiro-da-Silva, N. Santarém, and J. Tavares. 2021. IL-2 and IFN-γ are biomarkers of
  SARS-CoV-2 specific cellular response in whole blood stimulation assays. *medRxiv*2021.01.04.20248897.
- 484 34. van Kooyk, Y., and G. A. Rabinovich. 2008. Protein-glycan interactions in the 485 control of innate and adaptive immune responses. *Nat. Immunol.* 9: 593–601.
- 35. Netea, M. G., E. J. Giamarellos-Bourboulis, J. Domínguez-Andrés, N. Curtis, R. van
  Crevel, F. L. van de Veerdonk, and M. Bonten. 2020. Trained Immunity: a Tool for
  Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. *Cell* 181: 969–
  977.
- 36. Luo, M., J. Liu, W. Jiang, S. Yue, H. Liu, and S. Wei. 2020. IL-6 and CD8+ T cell
  counts combined are an early predictor of in-hospital mortality of patients with COVID19. *JCI Insight* 5.


493






494


Fig.1 – Peripheral T cell glycoprofile is altered upon SARS-CoV-2 infection at 495 diagnosis. Levels (Mean intensity fluorescence, MFI) of (A) L-PHA lectin binding, 496 detecting *β*1,6-GlcNAc branched *N*-glycans and (B) SNA lectin binding, detecting a-2,6 497 498 sialylation, in CD8<sup>+</sup>, CD4<sup>+</sup> and  $\gamma\delta$  T cell subsets of non-infected donors (Non-IF; n=5) and infected (IF; n=30) patients. Levels of (A) L-PHA and (B) SNA lectin binding for 499 each disease severity group: asymptomatic (Asympt.;n=5), mild (n=18), moderate 500 (Mod.; n=6) and recovered (Rec; n=2) Each dot represents one patient. Mann-Whitney 501 t-test was performed to evaluate statistically significance differences between each 502 503 group-pair. \* p-value<0.05, \*\*<0.005.





504

Figure 2 – Patient-derived serum induces a differential T cell glycosylation comparing 505 asymptomatic and symptomatic patients (A) L-PHA lectin and (B) SNA lectin binding 506 (MFI) of CD8<sup>+</sup> and CD4<sup>+</sup> T cells from a healthy donor, independent of our cohort, 507 508 incubated for 24-hours with 10% plasma from 4 patients from each group (Non-IF, asymptomatic or moderate). Each dot represents a subject. Gating strategies for each 509 population are included in Supplemental Figure 1A. Mann-Whitney t-test was 510 511 performed to evaluate statistically significance differences between each group-pair. \* *p*-value<0.05, \*\*<0.005. 512



513

Fig.3 – DC-SIGN expression in peripheral monocytes as a predictor of good vs. poor 514 prognosis in COVID-19 patients. (A) Levels of DC-SIGN surface expression (MFI) in 515 monocytes (Mo). (B) Receiver operating characteristic (ROC) curve plotted for the DC-516 SIGN expression levels in monocytes from COVID-19 patients. The distribution of DC-517 SIGN levels are represented regarding the prognosis, Px, (day 14; good Px in green and 518 poor Px in grey) as well as the severity at diagnosis. Each dot represents one patient 519 N=24. Gating strategies for each population are included in **Supplemental Figure 1A**. 520 Mann-Whitney t-test was performed to evaluate statistically significance differences. \* 521 p-value < 0.05, \*\* < 0.005, or represented. 522

523